---
title: BT-474-luc Orthotopic Model - TD2 Precision Oncology
description: BT-474-luc is a luminescent breast cancer cell line that facilitates the study of HER2-positive breast cancer and enables non-invasive monitoring of treatment responses.
image: https://td2inc.com/hubfs/Assets/GraphsFigures/bt-474-luc.png
---
×
[](https://td2inc.com/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
# BT-474-luc Orthotopic Model
**Synonyms:** BT474
BT-474-luc is a luminescent breast cancer cell line derived from the BT-474 model. This cell line overexpresses human epidermal growth factor receptor 2 (HER2) and exhibits luminescence due to the introduction of the luciferase gene. It serves as a valuable tool for studying HER2-positive breast cancer and evaluating therapeutic interventions. BT-474-luc allows for non-invasive monitoring of tumor growth and response to treatment using bioluminescence imaging techniques. Researchers utilize this model to investigate HER2 signaling, test targeted therapies, and assess drug efficacy in preclinical studies.
## Model Details
**Cancer Type:** Breast Cancer
**Model Name:** BT-474-luc
**Mouse Strain:** Rag1 KO
**Treatment Data Available:** N/A
## BT-474-luc Survival
Survival of BT-474-luc after intracranial injection in Rag1 KO mice (n=5)
### Request Additional Syngeneic Model Data
## CONTACT US
## Get Started.
Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.
[Get Started Now](https://td2inc.com/contact-us/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
Office
13208 E. Shea Blvd,
Suite 100
Scottsdale, AZ 85259
Phone
(602) 358-8300
Connect with us
-
-
© 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)